Navigation Links
Zix Corporation Reports Highest Revenue Quarter as Company Announces First Quarter 2009 Financial Results
Date:4/28/2009

Email Encryption business continues to drive performance for Company

DALLAS, April 28 /PRNewswire-FirstCall/ -- Zix Corporation (ZixCorp(R)), (Nasdaq: ZIXI), the leader in hosted services for email encryption and payor-sponsored e-prescribing, today announced financial results for the first quarter ended March 31, 2009. ZixCorp recorded first quarter revenues of $7.3 million and a GAAP net loss of $1.5 million for the quarter, or $0.02 per share, compared with revenues of $7.2 million, and a GAAP net loss of $1.7 million, or $0.03 per share, in the corresponding quarter in 2008. Adjusted net loss was $0.7 million, or $0.01 per share, compared with an adjusted net loss of $1.0 million, or $0.02 per share, in the corresponding quarter in 2008.

"I am pleased that, in this current economic environment, ZixCorp was able to record its highest revenue quarter ever, driven by the 18 percent year-on-year revenue growth in our Email Encryption business," said Rick Spurr, chairman of the board and chief executive officer. "We believe compliance will continue to drive demand for our Email Encryption services, whether because of our ability to conform to European standards through our newly-opened UK data center or the expansion of entities covered by HIPAA under the recently-enacted federal stimulus package. In fact, our recently-announced new partnership with Webroot provides further evidence of the growing demand for email encryption services. Our market leadership, superior SaaS architecture, and the largest shared directory of email addresses in the industry, with our management of encryption keys 'in the cloud,' indicate our Email Encryption business remains well-positioned for continued growth. In our PocketScript business, we continue to pursue larger payor contracts while we deploy new deals that were secured in the last two quarters. Despite recording revenue in this business of about half of last year's amount, as described later in this release, I am encouraged by the growth in usage by our physicians, where we saw year-over-year growth in scripts written on essentially the same-sized active prescriber base. This trend, combined with the incorporation of e-prescribing as an essential element of healthcare IT in the recently-enacted federal stimulus package, reinforces our belief that e-prescribing is a fundamental technology on which a connected healthcare system can be built."

Corporate Highlights

  • Company-wide first quarter 2009 revenue of $7.3 million is up 1 percent over the comparable quarter in 2008, meeting the upper half of previously-issued revenue guidance of $7.1 to $7.4 million
  • Cash and cash equivalents at March 31, 2009 were $12.2 million, reflecting a timing difference in payments of $1.1 million from two long-time customers expected in Q1 but not received until the middle of April. Accordingly, the Company considers the temporary decline in cash a normal part of the payment and receipt cycle
  • Adjusted earnings (see "Use of Non-GAAP Financial Information" below and the attached Reconciliation of GAAP to Non-GAAP Financial Measures) were ($0.01), meeting previously issued guidance of ($0.01) to ($0.02)

Business Highlights

Email Encryption

  • Email Encryption revenue for first quarter 2009 was $6.2 million, up 18 percent when compared with the same quarter in 2008
  • New first-year orders of $1.1 million, compared with $1.4 million in the same quarter in 2008. Total orders for the quarter were $7.4 million, compared with $8.7 in the first quarter of 2008
  • ZixCorp maintained a strong renewal rate for eligible contracts at 95 percent
  • The ZixDirectory(TM), the community of users which forms the backbone of ZixCorp's Email Encryption Service, achieved a new milestone, topping 16 million members at a growth rate of approximately 100,000 new addresses added each week
  • ZixCorp recently announced the establishment of a European data center in the United Kingdom to enable its European customers to comply with European Union privacy and security rules

e-Prescribing

  • e-Prescribing revenue for first quarter 2009 was $1.0 million compared with $1.9 million for the first quarter in 2008. This drop in revenue was due primarily to the decline in fee revenue after a contractual cap was reached in one payor program, the decrease in deployment revenues as the rate of new physician deployments has declined in 2008 and early 2009 when compared with 2007, as well as the first quarter 2008 impact of a one-time revenue item resulting from the achievement of certain performance-related metrics in a single contract
  • The Company's PocketScript business achieved the top end of the e-prescribing deployment guidance of 250 to 350 for the first quarter with 350 deployments
  • ZixCorp released PocketScript(R) 6.9, a new version of its e-prescribing application. This release provides more robust information to physicians at the point of care to enhance the decision support and leverages the latest standards to keep PocketScript current with its certifications
  • The Company signed an expansion contract with Blue Cross Blue Shield of Massachusetts covering up to 400 new prescribers
  • ZixCorp's PocketScript e-Prescribing service processed over 2.5 million e-scripts in the first quarter, an increase of 12 percent over the first quarter of 2008

Financial Highlights

Note: All gross profit and expenditure explanations below are based on adjusted non-GAAP amounts, the primary adjustment of which is non-cash stock-based compensation under SFAS 123R - see "Use of Non-GAAP Financial Information" below and the "Reconciliation of GAAP to Non-GAAP Financial Measures" presented with attached financial statements.

                    Revenues by Product First Quarter 2009

                                                     3-month Variance
                       3 Months Ended March 31,       2009 vs. 2008
                       ------------------------       -------------
                           2009         2008            $         %
                           ----         ----          ----      ----

    Email Encryption    $6,242,000    $5,289,000      953,000    18
    e-Prescribing        1,014,000     1,910,000     (896,000)  (47)
                         ---------     ---------    ---------
    Total revenues      $7,256,000    $7,199,000       57,000     1
                     ============= =============      ======== =====

Revenues: The increase in Email Encryption revenue was due to the growth inherent in a successful subscription model with steady additions to the subscriber base coupled with a high rate of renewing existing customers. The decline in e-Prescribing revenue was driven primarily by fewer new prescriber deployments in 2008 and early 2009 compared with 2007, which led to a decline in deployment fees, a drop in fee revenue after reaching a contractual cap in one customer program, and a first quarter 2008 one-time revenue catch-up. The Company's order backlog (contractually bound service contracts that represent future revenue to be recognized as the services are provided) was a record $38.4 million on March 31, 2009.

Gross Profit: The Company recorded an adjusted gross profit of $4.9 million (68 percent of revenue) for the first quarter 2009, compared with $4.7 million or 65 percent of revenue for the same period in 2008. The adjusted gross profit contribution by business unit was a record $5.3 million (84 percent) from Email Encryption and negative $0.4 million (negative 35 percent) from e-Prescribing. The gross profit improvement for the quarter came from solid revenue growth in Email Encryption on a largely fixed cost structure, partially offset by the decline in e-Prescribing revenues.

R&D and SG&A Expenditures: On an adjusted basis, the Company's R&D expenses were $1.6 million and $1.5 million in the first quarter of 2009 and 2008, respectively. SG&A expenses on an adjusted basis were $4.0 million and $4.3 million in the first quarter of 2009 and 2008, respectively, with the decline in 2009 due to the Company's ongoing cost reduction measures.

Adjusted Earnings: The Company recorded an adjusted net loss of $0.7 million, or $0.01 per share for the first quarter of 2009, compared with an adjusted net loss of $1.0 million or $0.02 per share for the comparable quarter in 2008. The improvement in adjusted net loss was driven primarily by the improvements in the gross margin and SG&A discussed above. See the attached "Reconciliation of GAAP and Non-GAAP Financial Measures" for a reconciliation of GAAP to non-GAAP line items.

Outlook: The Company forecasts revenue for the second quarter to be between $7.3 and $7.6 million. e-Prescribing deployments for the second quarter are expected to be between 300 and 350 deployments. Adjusted earnings (loss) per share is expected to be between $0.00 and ($0.01).

First Quarter Conference Call Information

The Company's first quarter operating results will be released after close of the U.S. financial markets on April 28, 2009. The Company will hold a conference call to discuss this information on April 28 at 5:00 p.m. ET.

A live Webcast of the conference call will be available on the investor relations portion of ZixCorp's Web site at http://investor.zixcorp.com. Alternatively, participants can listen to the conference call by dialing 617-614-6207 or toll-free 800-798-2884 and entering access code 15222301. An audio replay of the conference will be available until May 5, by dialing 617-801-6888 or toll-free 888-286-8010, and entering the access code 83271977, and after that date via Webcast on the company's Web site.

About Zix Corporation

Zix Corporation is the leader in email encryption and payor sponsored e-prescribing services. ZixCorp offers the simplicity of Software as a Service with the convenience of customizable encryption policies. ZixCorp provides automated key management "in the cloud" for all its customers, resulting in a scalable, reliable, easy-to-use and simple-to-administer service. ZixDirectory is the largest email encryption directory in the world enabling seamless and secure communication among communities of interest. ZixDirectory connects over 16 million members and includes over 800 financial institutions, the FFIEC federal banking regulators, 20 state banking regulators, over 30 Blue Cross Blue Shield organizations and more than 1000 hospitals. ZixCorp's PocketScript(R) e-prescribing service saves lives and saves money by automating the prescription process between payors, doctors and pharmacies. For more information visit http://www.zixcorp.com/.

ZixCorp Contacts:

Public Relations: Geoff Bibby (214) 370-2241, publicrelations@zixcorp.com

Investor Relations: Peter Wilensky (214) 515-7357, invest@zixcorp.com

Safe Harbor Statement for ZixCorp

The following is a "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995. The following statements of Mr. Spurr, "We believe compliance will continue to drive demand for our Email Encryption services, whether because of our ability to conform to European standards through our newly-opened UK data center or the expansion of entities covered by HIPAA under the recently-enacted federal stimulus package. In fact, our recently-announced new partnership with Webroot provides further evidence of the growing demand for email encryption services. Our market leadership, superior SaaS architecture, and the largest shared directory of email addresses in the industry, with our management of encryption keys 'in the cloud,' indicate our Email Encryption business remains well-positioned for continued growth. In our PocketScript business, we continue to pursue larger payor contracts while we deploy new deals that were secured in the last two quarters. Despite recording revenue in this business of about half of last year's amount, as described later in this release, I am encouraged by the growth in usage by our physicians, where we saw year-over-year growth in scripts written on essentially the same-sized active prescriber base. This trend, combined with the incorporation of e-prescribing as an essential element of healthcare IT in the recently-enacted federal stimulus package, reinforces our belief that e-prescribing is a fundamental technology on which a connected healthcare system can be built.", and the statements under the caption "Outlook" are forward-looking statements, not a guarantee of future performance, and involve risks and uncertainties. Actual results may differ materially from those projected in these forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the Company's continued operating losses and its PocketScript e-Prescribing service's use of cash resources; the Company's ability to achieve broad market acceptance for the Company's products and services, including the Company's ability to enter into new or expand existing sponsorship agreements for its PocketScript e-Prescribing business and the Company's ability to continue realizing acceptance of its Email Encryption business in its core markets of healthcare and financial and to achieve market acceptance of its Email Encryption business in other markets; the Company's ability to maintain existing and generate other revenue opportunities, including fees for scripts written or value added services for its payer customers from its PocketScript e-Prescription business; the Company's ability to establish and maintain strategic and OEM relationships to gain customers and grow revenues, particularly in its Email Encryption business; the ability of the Company's PocketScript e-prescribing service to compete against the products of other vendors who offer a more comprehensive array of IT solutions to the healthcare industry; the effect of the ongoing global recession on the Company's business, including its affect on customers and their financial wherewithal and buying patterns; the expected increase in competition in the Company's Email Encryption and e-Prescription businesses; the effect of government regulations and forthcoming federal funding for health information technologies; the Company's ability to successfully and timely introduce new Email Encryption and e-Prescription products and services or related products and services and implement technological changes; and other risks, uncertainties and factors that could affect our business and could cause in actual results to differ materially from those projected in the forward-looking statements as referred to our Annual Report on Form 10-K for the fiscal year ended December 31, 2008, as filed with the U.S. Securities and Exchange Commission and available at http://www.sec.gov/, as updated in our Quarterly Reports on Form 10-Q filed after such Form 10-K. We disclaim any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments, or otherwise.

Use of Non-GAAP Financial Information

Management evaluates and makes operating decisions using various performance measures. In addition to reporting financial results in accordance with GAAP, we also consider when making financial decisions, non-GAAP gross profit, operating income/(loss), net income/(loss), and earnings/(loss) per share which we refer to as "adjusted gross profit," "adjusted operating income/(loss)," "adjusted net income/(loss)," and "adjusted earnings/(loss) per share." In calculating adjusted gross profit, adjusted operating income/(loss), adjusted net income/(loss), and adjusted earnings/(loss) per share, management excludes certain items to facilitate its review of the comparability of the Company's operating performance on a period-to-period basis because such items are not, in management's review, related to the Company's ongoing operating performance.

We present adjusted gross profit, adjusted operating income/(loss), adjusted net income/(loss), and adjusted earnings/(loss) per share because we consider each to be an important supplemental measure of our performance. Management uses these non-GAAP financial measures to make operational and investment decisions, to evaluate the Company's performance, to forecast and to determine compensation. Further, management utilizes these performance measures for purposes of comparison with its business plan and individual operating budgets and allocation of resources

We believe that these non-GAAP financial measures are useful to investors in providing greater transparency to the information used by management in its operational decision making. We believe that calculating adjusted gross profit, adjusted operating income/(loss), adjusted net income/(loss), and adjusted earnings/(loss) per share also facilitates a comparison of ZixCorp's underlying operating performance with that of other companies in our industry, which may from time to time use similar non-GAAP financial measures to supplement their GAAP results. However, non-GAAP measures have limitations as analytical tools, and you should not consider these measures in isolation or as a substitute for GAAP gross profit, operating income/(loss), and net income/(loss), and earnings/(loss) per share, or any other performance measure determined in accordance with GAAP. In the future, we expect to continue to incur expenses similar to certain of the non-GAAP adjustments described above and exclusion of these items in the presentation of our non-GAAP financial measures should not be construed as an inference that all of these costs are unusual, infrequent or non-recurring.

Investors and potential investors are encouraged to review the reconciliation of non-GAAP financial measures contained within this press release with our GAAP gross profit, operating income and net income. For more information, see the consolidated statements of income and the "Reconciliation of GAAP to Non-GAAP Financial Measures" contained in this press release.

                                   ZIX CORPORATION
                       CONDENSED CONSOLIDATED BALANCE SHEETS

                                                      March 31,   December 31,
                                                        2009          2008
                                                     (unaudited)    (audited)
                                                     -----------    ---------
    ASSETS
    Current assets:
      Cash and cash equivalents                     $12,228,000   $13,245,000
      Marketable securities                              25,000             -
      Receivables, net                                  706,000       476,000
      Prepaid and other current assets                1,236,000     1,145,000
                                                      ---------     ---------
        Total current assets                         14,195,000    14,866,000
    Restricted cash                                           -        28,000
    Property and equipment, net                       2,362,000     2,236,000
    Goodwill and other assets                         2,219,000     2,227,000
                                                      ---------     ---------
        Total assets                                $18,776,000   $19,357,000
                                                    ===========   ===========


    LIABILITIES AND STOCKHOLDERS' DEFICIT
    Current liabilities:
      Accounts payable and accrued expenses          $3,536,000    $2,916,000
      Deferred revenue                               14,201,000    14,960,000
                                                     ----------    ----------
        Total current liabilities                    17,737,000    17,876,000
    Long-term liabilities:
      Deferred revenue                                2,764,000     2,484,000
      Deferred rent                                     284,000       300,000
                                                        -------       -------
        Total long-term liabilities                   3,048,000     2,784,000
                                                      ---------     ---------
        Total liabilities                            20,785,000    20,660,000
        Total stockholders' deficit                  (2,009,000)   (1,303,000)
                                                    -----------   -----------
        Total liabilities and stockholders'
         deficit                                    $18,776,000   $19,357,000
                                                    ===========   ===========



                                ZIX CORPORATION
                CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                  (Unaudited)

                                              Three Months Ended March 31,
                                              ----------------------------
                                                    2009          2008
                                                    ----          ----
    Revenues                                    $7,256,000    $7,199,000

    Cost of revenues                             2,471,000     2,580,000
                                                 ---------     ---------
    Gross profit                                 4,785,000     4,619,000
    Operating expenses:
      Research and development                   1,731,000     1,545,000
      Selling, general and administrative        4,644,000     4,817,000
                                                 ---------     ---------
        Total operating expenses                 6,375,000     6,362,000
                                                 ---------     ---------

    Operating loss                              (1,590,000)   (1,743,000)

    Investment and other income                     68,000       116,000
                                                    ------       -------

    Loss before income taxes                    (1,522,000)   (1,627,000)
    Provision for income taxes                      20,000        77,000
                                                    ------        ------

    Net loss                                   $(1,542,000)  $(1,704,000)
                                              ============  ============

    Basic and diluted loss per common share         $(0.02)       $(0.03)
                                                   =======       =======

    Basic and diluted weighted average
     common shares outstanding                  63,319,482    62,703,846
                                                ==========    ==========



                                 ZIX CORPORATION
                  CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (Unaudited)

                                                  Three Months Ended March 31,
                                                   ---------------------------
                                                        2009          2008
                                                        ----          ----
    Operating activities:
      Net loss                                     $(1,542,000)  $(1,704,000)
      Non-cash items in net loss                     1,163,000     1,105,000
      Changes in operating assets and
       liabilities                                    (497,000)      856,000
                                                     ---------     ---------
        Net cash provided by (used in) operating
         activities                                   (876,000)      257,000

    Investing activities:
      Purchases of property and equipment             (144,000)      (71,000)
      Restricted cash investments and marketable
       securities, net                                   3,000     1,734,000
                                                       -------     ---------
        Net cash provided by (used in) investing
         activities                                   (141,000)    1,663,000

    Financing activities:
      Proceeds from exercise of stock options                -       141,000
                                                     ---------     ---------
        Net cash provided by financing activities            -       141,000
                                                     ---------     ---------

    Increase (decrease) in cash and cash
     equivalents                                    (1,017,000)    2,061,000
    Cash and cash equivalents, beginning of
     period                                         13,245,000    10,524,000
                                                    ----------    ----------
    Cash and cash equivalents, end of period       $12,228,000   $12,585,000
                                                   ===========   ===========



                                ZIX CORPORATION
             RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
                                  (Unaudited)

                                      Three Months Ended March 31, 2008
                                     ---------------------------------

                                        Non-Cash
                                       Stock-based    Income Tax    Non-GAAP
                               GAAP    Compensation     Impact    ("Adjusted")
                              Results      (A)           (B)       Net Income
                              -------  -----------    ---------    ----------

    Revenues                $7,256,000           $-          $-    $7,256,000

    Cost of revenues         2,471,000      126,000           -     2,345,000
                             ---------      -------     -------     ---------
    Gross profit             4,785,000      126,000           -     4,911,000
    Operating expenses:
      Research and
       development           1,731,000      101,000           -     1,630,000
      Selling, General
       and administrative    4,644,000      609,000           -     4,035,000
                             ---------      -------     -------     ---------
      Total operating
       expenses              6,375,000      710,000           -     5,665,000
                             ---------      -------     -------     ---------
    Operating income/(loss) (1,590,000)     836,000           -      (754,000)

    Investment and
     other income               68,000            -           -        68,000
                                ------      -------     -------        ------
    Income/(loss)
     before income taxes    (1,522,000)     836,000           -      (686,000)
    Provision for
     income taxes               20,000            -      (8,000)       12,000
                                ------      -------     -------        ------
    Net income/(loss)      $(1,542,000)    $836,000      $8,000     $(698,000)
                          ============     ========      ======    ==========
    Basic and Diluted
     loss per common
     share                      $(0.02)       $0.01          $-        $(0.01)
                               =======        =====          ==   ===========
    Basic and diluted
     weighted average
     common shares
     outstanding            63,319,482   63,319,482  63,319,482    63,319,482
                            ==========   ==========  ==========    ==========

    (A) Non-cash stock-based compensation charges relating to stock option
    grants awarded to employees and third-party service providers and
    accounted for in accordance with SFAS123(R), "Share-Based Payment."

    (B) The Company's U.S. operations' net losses for US tax purposes are
    fully provisioned.  The non-GAAP provision for income taxes represents
    expected cash taxes to be paid.



                               ZIX CORPORATION
            RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
                                 (Unaudited)

                                    Three Months Ended March 31, 2008
                                    ---------------------------------
                                        Non-Cash
                                       Stock-based    Income Tax   Non-GAAP
                               GAAP    Compensation     Impact   ("Adjusted")
                              Results      (A)           (B)      Net Income
                              -------  -----------    ---------  ----------

    Revenues                $7,199,000         $-         $-     $7,199,000

    Cost of revenues         2,580,000     79,000          -      2,501,000
                             ---------     ------          -      ---------
    Gross profit             4,619,000     79,000          -      4,698,000
    Operating expenses:
      Research and
       development           1,545,000     66,000          -      1,479,000
      Selling, general
       and administrative    4,817,000    511,000          -      4,306,000
                             ---------    -------          -      ---------
      Total operating
       expenses              6,362,000    577,000          -      5,785,000
                             ---------    -------          -      ---------
    Operating
     income/(loss)          (1,743,000)   656,000          -     (1,087,000)

    Investment and
     other income              116,000          -          -        116,000
                               -------          -          -        -------
    Income/(loss)
     before income taxes    (1,627,000)   656,000          -       (971,000)
    Provision for
     income taxes               77,000          -          -         77,000
                                ------          -          -         ------
    Net income/(loss)      $(1,704,000)  $656,000         $-    $(1,048,000)
                           ============  ========         ==   ============
    Basic and diluted
     loss per common share      $(0.03)     $0.01         $-         $(0.02)
                               =======      =====         ==        =======
    Basic and diluted
     weighted average
     common shares
     outstanding            62,703,846 62,703,846 62,703,846     62,703,846
                            ========== ========== ==========     ==========

    (A) Non-cash stock-based compensation charges relating to stock option
    grants awarded to employees and third-party service providers and
    accounted for in accordance with SFAS123(R), "Share-Based Payment."

    (B) Actual cash taxes to be paid are consistent with the GAAP provision
    for income taxes.


'/>"/>
SOURCE Zix Corporation
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Brooke Franchise Corporation Announces Selected July Results
3. MedThink Communications Retained by NanoBio Corporation
4. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
5. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
6. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
7. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
8. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
9. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
10. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
11. AGA Medical Corporation Receives Approval for the AMPLATZER Muscular Ventricular Septal Defect Occluder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... , June 24, 2016 ... of the "Structural Electronics 2015-2025: Applications, Technologies, ... In-Mold Electronics, Smart Skin, ... Photovoltaics Structural electronics involves electronic ... load-bearing, protective structures, replacing dumb structures such as ...
Breaking Medicine Technology: